CTRI/2016/01/006515已完成3 期
A Multi-Centre, Randomized, Double Blind, Parallel-Group, Comparative Clinical Trial to evaluate the Safety and Clinical Equivalence of Generic Clotrimazole Troche/Lozenges USP,10mg (manufactured by Unique Pharmaceutical Laboratories, India) to Clotrimazole Troche/Lozenges® 10mg (Roxane Laboratories Inc., USA) in subjects with OropharyngealCandidiasis ?. - TPC-CLT-002
THINQ Pharma CRO Private Limited0 个研究点目标入组 271 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 271
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Presence of specific signs and symptoms of Oropharyngeal Candidiasis, including erythematous areas, white patches(thrush), mouth pain, irritation, burning, glossitis, altered taste, pruritis, dysphagia and odynophagia.
- •2. Clinical examination of oropharynx consistent with a diagnosis of oral candidiasis (such as creamy, white, curd-like patches of thrush ? or erythematous lesions on mucosal surfaces).
- •3. Confirmation of Candidiasis by findings on direct microscopic examination (potassium hydroxide smear) consistent with Candida species or positive fungal culture for Candida species, with culture obtained in the 2 days preceding initiation of therapy with the study drug.
- •4. Subjects who are able and willing to give Informed Consent.
排除标准
- •1. Female subjects who are pregnant, lactating or planning to become pregnant during the study period.
- •2. Subjects diagnosed with disseminated candidiasis or requiring systemic antifungal therapy.
- •3. Subjects diagnosed with hairy leukoplakia.
- •4. Presence of only perioral lesions, e.g., angular chelitis.
- •5. History of intolerance or sensitivity to clotrimazole (or other imidazole or azole compounds) or any constituent of Roxane ® or the generic Clotrimazole Troche/ Lozenges or unable to tolerate oral medication.
- •6. Subjects having history of resistance to treatment with clotrimazole (Subject who are resistant to clotrimazole after culture and sensitivity test have to be excluded from the study).
- •7. Subjects who have received any oral or systemic antifungal therapy within fourteen (14) days prior to randomization.
- •8. Subjects who have received any investigational therapy within 30 days prior to randomization.
- •9. Subjects who have been diagnosed with any concomitant condition that, in the opinion of the investigator, could interfere with the evaluation of efficacy or safety, or would make it unlikely that the subject would complete the study.
- •10. Subjects who have been treated with protease inhibitors for the first time within 30 days.
- •11. Subjects who have been taking medications known to have significant interaction with azoles (e.g., antacids, H2-receptor blockers, rifampin, phenytoin, carbamazepine, astemizole).
- •12. Subjects who have a history of candidal prophylaxis with any azole antifungal medication.
- •13. Any subject with recurrent Oropharyngeal Candidiasis.
- •14. Any subject who is chronically infected with Candida.
- •15. Any subject with baseline liver function tests greater than 3 times the upper limit of normal (ULN).
- •16. CD4 cell count less than 200 cells/mm3.
- •17. Absolute neutrophil count less than 500/mm3.
- •18. Subject with history of Type II Diabetes Mellitus with Uncontrolled Blood Sugar levels. (I.e. Random Blood Sugar level > 350).
- •19. Suspected inability (or) unwillingness to comply with the study procedures.
研究者
相似试验
已完成
4 期
Effect of probiotic Bacillus clausii UBBC07 in children with Acute DiarrhoeaCTRI/2017/08/009543nique Biotech Ltd119
已完成
3 期
Effect of probiotic Bacillus coagulans Unique IS2 in Adults with ConstipatioCTRI/2017/11/010539nique Biotech Ltd100
已完成
不适用
A Clinical Trial to see effect of Bacillus subtilis HU58 and Bacillus coagulans SC208 syrup in treatment of acute diarrhoea in childreCTRI/2021/10/037398Synergia Life Sciences Pvt Ltd64
已完成
不适用
A Clinical Trial to see effect and Safety of Bacillus subtilis HU58 plus Bacillus coagulans SC208 Capsules in subjects with irritable bowel syndrome with diarrhoeaCTRI/2022/07/044154Synergia Life Sciences Pvt Ltd A Novozymes One Health Company
进行中（未招募）
不适用
A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled,Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg-300mg once daily) in Elderly Subjects with Major Depressive DisorderMajor Depressive Disorder (MDD)EUCTR2004-004409-24-DEGlaxoSmithKline Research & Development364